Impact of a Biophoton Therapy on Patients With Brain Disorders

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorFirst Institute of All Medicines

About this trial

Previous clinical studies revealed that the newly developed biophoton therapy has been safe and effective in treating patients with Alzheimer's disease, dementia, stroke, traumatic brain injury, or Parkinson's disease. The current study is to confirm the previous clinical observation by conducting as a randomized, triple-blinded, placebo-controlled prospective intervention clinical research. About 80 patients with brain disorder (Alzheimer's disease, dementia, stroke, traumatic brain injury, Parkinson's disease) will participate in the intervention clinical study at the Tesla MedBed Center located in Butler, PA.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Must meet conditions for approval.

Must be 18-years or older and stay in a hotel.

Must have a caregiver willing to support the participant's full involvement in the study. • The caregiver can assist in completing all study surveys.

Can provide informed consent or can be assisted by caregiver.

Disqualifiers

Any untreated mental illnesses, that would affect study participation. This will be judged by the caregiver, or by the clinical study medical expert.

Someone that relies on a ventilator.

Someone who has a deep brain stimulator, pacemaker, or any implanted electronic devices.

Co-morbid conditions that would interfere with study activities or response to treatment, which may include severe chronic pulmonary disease, history of uncontrolled seizures, acute or chronic infectious illness, severe diabetes, kidney failure, or any end-of-life prognosis.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Biophotonizer - a Biophoton Generator

    Device

    A biophotonizer is a device producing strong biophoton field. These biophotons help the human body to gain self-healing capacity to heal many disorders, including brain disorders.

Treatment groups

80 Participants
are divided into 2 treatment groups
Group A: Treatment GroupExperimental treatment 1 intervention
Group B: Control GroupPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

Overall Life Quality impacted by Biophoton Therapy

Short Form Health Survey (SF-36) will be used to assess life quality: scored from 0 (worst health) to 100 (best heath).

Time frame
0-2 weeks, 0-4 weeks after starting the study treatment.
2

Cognitive Capacity impacted by Biophoton Therapy

Montreal Cognitive Assessment (MOCA), Score below 10, severe cognition damage; 26-30, normal cognition.

Time frame
0-2 weeks, 0-4 weeks after starting the study treatment.

Secondary outcomes

1

Neurological Examination impacted by Biophoton Therapy

Neurological Examination by a Study Physician. The higher the score, the healthier the participant.

Time frame
0-2 weeks, 0-4 weeks after starting the study treatment.
2

Brain function change impacted by Biophoton Therapy

Brain function change is to be detected by using an EEG machine. Eye reaction time - the shorter the healthier.

Time frame
0-2 weeks, 0-4 weeks after starting the study treatment.
3

Brain Bio-Energy impacted by Biophoton Therapy

Using Bio-Well GDV Camera device and calculated by multiplication of areas of the brain. The more balanced joules, the better brain energy.

Time frame
0-2 weeks, 0-4 weeks after starting the study treatment.
4

Blood Circulation impacted by Biophoton Therapy

FALCON QUAD measures circulation using the ankle-brachial index. The more balanced measurement, the better blood circulation.

Time frame
0-2 weeks, 0-4 weeks after starting the study treatment.

Other outcomes

1

Safety of the Study participant impacted by Biophoton Therapy

Number of participants with treatment-related adverse events as assessed by CTCAEv4.0

Time frame
0-2 weeks, 0-4 weeks after starting the study treatment.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.